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Background: Sam-Hwang-Sa-Sim-Tang (SHSST) is a traditional Oriental medication that has been commonly used
in Korea for the treatment of hypertension, insomnia, and chest pain. In addition, some studies reported that
administration of SHSST results suppression of hyperlipidemia in rats or lowering lipid plasma level such as total
cholesterol (TC). Those results made us find and demonstrate positive effect of SHSST much more. The aim of the
current study was to examine whether SHSST exerts an effect against hepatic steatosis and two type of SHSST has
different efficacy on liver steatosis.
Methods: Total 40 mice were divided randomly and equally into 4 groups: a normal diet (CON) group, high-
cholesterol diet (HC) group, and treatment groups fed a high-cholesterol diet (HCD) with a 30% or 80% ethanol
extract of SHSST (SHSST-L and SHSST-H, respectively). The HCD was given for 9 weeks. The SHSST-treated groups
were orally administered SHSST at a dose of 150 mg/kg, whereas the other groups received physiological saline.
Results: SHSST administration to mice resulted in a decline in serum levels of total cholesterol and low-density
lipoprotein. Histological examination showed that lipid droplets were smaller in the SHSST-treated group than in
the HC group. At the protein level, expression of sterol regulatory element-binding protein 2 (SREBP-2) was
suppressed by SHSST. In addition, the mRNA expression of cholesterol metabolism-related molecules such as
SREBP-2, liver X receptor (LXR), low-density lipoprotein receptor (LDLR), and 3-hydroxy-3methylglutary-CoA
(HMG-CoA) was also suppressed in SHSST-treated groups in the liver. In the aorta tissue, SHSST decreased the
expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), intercellular adhesion molecule-1 (ICAM-1), vascular
cell adhesion molecule-1(VCAM-1), transforming growth factor (TGF)-β1, and fibronectin.
Conclusions: The present study indicates that SHSST protects against liver steatosis and protects vessels against
inflammation arising from excessive ingestion of cholesterol. These findings may also suggest that SHSST could be
used as an adjuvant remedy for protection against liver steatosis.
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Metabolic syndrome is a group of conditions that in-
crease the risk of diabetes, cardiovascular diseases, and
carcinogenesis [1]. Genetic and environmental factors
are considered to promote the development of meta-
bolic syndrome. In addition, obesity, diabetes, and non-
alcoholic fatty liver disease (NAFLD) are common in* Correspondence: kook@sj.ac.kr
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reproduction in any medium, provided the ormetabolic syndrome [2,3]. NAFLD frequently causes ab-
normal liver function, and one of the characteristic fea-
tures of NAFLD is hepatic steatosis [4]. The role of
dietary cholesterol, with the subsequent increased hep-
atic esterification of cholesterol and its association to
hepatic triglyceride accumulation, is a new paradigm for
hepatic steatosis [5]. Although hepatic steatosis can
proceed to end-stage liver disease, ideal treatment for
this disease has not yet been established. Therefore, pre-
vention of hepatic steatosis may be useful for popula-
tions at risk of advanced liver disease [6,7].. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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herbs; Coptidis rhizoma of the Ranunculaceae family
(rhizomes of Coptis chinensis; CC), Scutellariae radix of
the Labiatae family (roots of Scutellaria baicalensis; SB),
and Rhei rhizoma of the Polygonaceae family (rhizomes
of Rheum officinale; RO). In traditional Korean medi-
cine, SHSST has been commonly prescribed for hyper-
tension, insomnia, and chest pain [8-10]. Recent studies
have also reported various beneficial effects of SHSST,
including anti-inflammatory, antihypertensive, antiathero-
genic, and antioxidant effects [11-14]. In addition, there
were studies that reported SHSST-administrated rats
showed the tendency of decline of several lipid plasma
levels including total cholesterol and administration of
SHSST suppressed the development of hyperlipememia
[10,11]. Generally, liver is considered as central organ in
lipid metabolism [15,16]. Therefore, those previous studies
made us think SHSST might show those positive effects
because of some positive connection with metabolic role
of liver. Plus, several studies have suggested that the effi-
cacy of herbs could differ depending on the type of solv-
ent, e.g., water, methanol, or ethanol, or the concentration
of solvent used to extract the active ingredient [17-20].
Taking into all those facts account, we decided to
study the positive effect of SHSST related with lipid me-
tabolism specifically in liver. We finally hypothesized
that SHSST might have a protective effect against hep-
atic steatosis induced by a high-cholesterol diet (HCD)
because hepatic steatosis induced by HCD is basic fea-
tures of NAFLD and it is also one of general patho-
logical status closely related with lipid metabolism. In
addition, we also hypothesized the efficacy of SHSST
against hepatic steatosis may differ depending on the
concentration of ethanol used to extract active ingredi-
ents from SHSST. In addition, because the protective ef-
fect of SHSST against hepatic steatosis is not known, we
decided to study the effects of SHSST in mice with hep-
atic steatosis induced by HCD. To our knowledge, this is
the first study to evaluate the efficacy of SHSST against
liver steatosis according to the concentration of ethanol
used for extraction of SHSST.
Methods
Reagents
CF, SG, and RB were purchased from Omniherb Co. Ltd
(Daegu, Republic of Korea). The normal diet and HCD
were obtained from Research Diets (New Brunswick, NJ,
USA). The other reagents were purchased from Sigma-
Aldrich (St. Louis, MO, USA), unless otherwise specified
in the text.
Preparation of SHSST
SHSST consists of CC, SB, and RO. Each herb was used
in a ratio of 1:1:1 (300 g: 300 g:300 g). The herbs had amoisture content of <11% by weight and were air-dried.
The combination of herbs was subjected to extraction
with 30% or 80% (v/v) ethanol in water at 60°C for 8 h.
The extracts were filtered with 10 μM cartridge paper,
and the ethanol was removed via vacuum rotary evapor-
ation (Eyela, Japan). The concentrates were freeze-dried,
and the yields were 13% and 15% for the 30% and 80%
ethanol extracts, respectively. The powders were dis-
solved in distilled water for the experiments, and the re-
sidual powders were stored at −20°C.
Animal experiments
Forty male C57BL/6 J mice weighing 18–19 g at the age of
3 weeks were purchased from Daehan Biolink (Daejeon,
Republic of Korea). The animals were all maintained in
accordance with conditions recommended according to
the National Institutes of Health guidelines. The Institu-
tional Animal Care Committee of Sangji University is ac-
cording to the NIH guidelines. This study was submitted
recommended by the Institutional Animal Care Commit-
tee of Sangji University (reg. no. 2012–3). The mice were
adapted to the feeding conditions for 2 weeks. They were
then given free access to food and tap water for 9 weeks
and were housed under a 12 h light/dark cycle at a con-
stant temperature of 22°C ± 2°C and relative humidity of
55% ± 10%. The mice were randomly separated into 6
groups of 10 mice each: the normal diet (CON) group,
HCD (HC) group, and treatment groups fed HCD with
the 30% or 80% ethanol extract of SHSST (L and H, re-
spectively). Mice except CON group consumed HCD
(D12108; Research Diets Inc., New Brunswick, New
Jersey, USA) containing 20.1% saturated fat, 1.37% choles-
terol, and 0% sodium cholate. The SHSST-treated groups
were orally administered with SHSST at a dose of 150 mg/
kg. The other groups were administered the same volume
of physiological saline. Body weight and dietary intake
were recorded every week. At the end of this period, the
animals were fasted overnight. The following day, they
were anesthetized with Zoletil (Virbac, Carros Cedex,
France), and blood samples were then collected by
cardiac puncture. The liver and aorta tissue were then
excised, rinsed, weighed, and directly stored at −80°C
until analysis.
Serum analysis
Serum concentrations of total cholesterol (TC), low-
density lipoprotein (LDL), alanine aminotransferase (ALT),
and blood urea nitrogen (BUN) were determined by en-
zymatic methods with commercial kits (Biovision Research
Products, Inc., CA, USA).
Histological analysis
Livers from representative mice in each group were fixed
in 10% buffered formalin, embedded in paraffin, and cut
Table 1 Primer sequences and PCR conditions
Gene name Tm (°C) Size (bp) Sequence 5′-3′
Sterol regulatory element binding transcription factor 2 55 177 F: GGCCTCTCCTTTAACCCCTT
R: CACCATTTACCAGCCACAGG(SREBP2)
Liver X receptor 55 119 F: TCCTACACGAGGATCAAGCG
(LXR) R: AGTCGCAATGCAAAGACCTG
Low density lipoprotein receptor 55 173 F: GCGTATCTGTGGCTGACACC
(LDLR) R: TGTCCACACCATTCAAACCC
3-hydroxy-3methylglutary-CoA 55 151 F: GTGGCAGAAAGAGGGAAAGG
R: CGCCTTTGTTTTCTGGTTGA(HMG-CoA)
Tumor necrosis factor alpha 55 275 F: AACATCCAACCTTCCCAAACG
(TNFα) R: GACCCTAAGCCCCCAATTCTC
Interleukin 6 55 162 F: TTGCCTTCTTGGGACTGATG
(IL-6) R: CCACGATTTCCCAGAGAACA
Intercelluar adhesion molecule 1 55 176 F: GTGGGTCGAAGGTGGTTCTT
(ICAM1) R: GCAGTTCCAGGGTCTGGTTT
Vascular cell adhesion molecule 1 55 163 F: CTCAGGTGGCTGCACAAGTT
(VCAM1) R: AGAGCTCAACACAAGCGTGG
Transforming growth factor beta1 55 169 F: GCGGCAGCTGTACATTGACT
(TNFβ) R: CCGGGTTGTGTTGGTTGTAG
Fibronectin 1 55 197 F: AGCTTTTCCCTGCACCTGAT
R: GGTGGGTGTCACCTGACTGA
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stained with hematoxylin and eosin (H&E) for histo-
logical examination of fat droplets. Images were acquired
using an SZX10 microscope (Olympus, Tokyo, Japan).
Western blot
The liver tissues were homogenized in commercial lysis
buffer PRO-PREP® (Intron Biotechnology Inc, Gyeongi-
do, Republic of Korea) and then incubated for 25 min
on ice to induce cell lysis. The samples were centrifugedFigure 1 Effects of SHSST on food intake. Values have been
expressed for 10 mice per group. 1)Food intake per mouse = amount
of total food intake in each group (g)/number of mice in
each group.at 13,000 rpm (4°C) for 5 min, and the supernatant was
transferred to a new 1.5 mL tube. The protein concen-
tration was determined using the Bio-Rad protein assay
reagent according to the manufacturer’s instructions
(Bio-Rad, Hercules, CA, USA). Protein samples (16 μg)
were electroblotted onto a poly-vinyl difluoride (PVDF)
membrane following separation on a 10% sodium dode-
cyl sulfate (SDS)-polyacrylamide gel. Membranes were
blocked with a 5% skim milk solution at 4°C for 1 h. The
membranes were incubated overnight with anti-SREBP-2
(Santa Cruz, CA, USA) as the primary antibody. Blots
were washed 3 times with Tween 20/Tris-buffered saline
(TTBS). After the blots were incubated with the corre-
sponding secondary antibody (Santa Cruz, CA, USA) for
1 h at room temperature, they were washed 3 times with
TTBS and were then developed using enhanced chemilu-
minescence (ECL) on X-ray film (Amersham Life Science,
Buckinghamshire, UK).Table 2 Body weights (g) at starting week and final week
respectively
CON HC SHSST-L SHSST-H
Start week (0) 22.49 ± 1.08 22.13 ± 0.95 22.72 ± 1.37 22.9 ± 1.09
Final week (9) 25.75 ± 1.12 25.7 ± 1.12 23.76 ± 2.22 23.7 ± 0.92
Values have been expressed as the mean ± SEM values of 10 mice per group.
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Each liver and aorta sample was homogenized, and total
RNA was isolated using the Easy-Blue® Reagent (Intron
Biotechnology Inc, Gyeongi-do, Republic of Korea) ac-
cording to the manufacturer’s instructions. Total RNA
was quantified using an Epoch® micro-volume spectro-
photometer system (BioTek Instruments, Inc. Winooski,
VT, USA). In brief, total RNA from the liver and aorta
samples was converted to cDNA by using a high-
capacity cDNA reverse transcription kit (Applied Biosys-
tems, Foster City, CA, USA). Reverse transcription was
conducted in a thermocycler (Gene Amp® PCR system
9700, Applied Biosystems) with the following program:
initiation for 10 min at 25°C, followed by incubation at
50°C for 90 min and at 85°C for 5 min. The cDNA synthe-
sized was then stored at −20°C. Real-time PCR analysis
was conducted using a Step One Plus® Real-time PCR sys-
tem (Applied Biosystems). SYBR® Green master mix and
primers were used for PCR analysis of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), sterol regulatory
element-binding protein 2 (SREBP-2), liver X receptor
(LXR), low-density lipoprotein receptor (LDLR), and 3-
hydroxy-3methylglutary-CoA (HMG-CoA) in liver tissue
and for GAPDH, tumor necrosis factor-α (TNF-α),
interleukin-6 (IL-6), intercellular adhesion molecule-1Figure 2 Effects of SHSST on LDL and TC in experimental mice.
(A) Serum level of LDL (B) Serum level of TC, CON, standard diet
group; HC, high cholesterol diet group; SHSST-L, HC plus 30% etha-
nol extract of SHSST treatment group, SHSST-H, HC plus 80% ethanol
extract of SHSST treatment group. Values have been expressed as
the mean ± SEM values of 10 mice per group. ###p < 0.001 vs. CON
group. *p < 0.05 vs. HC group, ***p < 0.001 vs. HC group.(ICAM-1), vascular cell adhesion molecule-1(VCAM-1),
transforming growth factor (TGF)-β1, and fibronectin in
aorta tissue (Santa Cruz, CA, USA). The PCR cycling pa-
rameters were as follows: 10 min at 95°C; 40 cycles of 5 s
at 95°C and 45 s at 60°C; and a final melting curve of 15 s
at 95°C, 1 min at 60°C, and 15 s at 95°C. All primer se-
quences and annealing temperatures are shown in
Table 1. Gene expression was calculated according to
the comparative threshold cycle (Ct) method (Applied
Biosystems).
Statistical analysis
All the values reported have been expressed as the mean ±
SEM values for 10 mice. Data were analyzed using one-
way analysis of variance (ANOVA) with Dunnett’s test.
Statistical analysis was performed using GraphPad Prism
(version 5).
Results
Effects of SHSST on body weight and food intake
Figure 1 shows the food intake of each group. There
were no significant differences between the HC group
and the SHSST-treated group with regard to food intake.
Table 2 shows the total body weight of mice at theFigure 3 Effects of SHSST on ALT and BUN in experimental
mice. (A) Serum level of ALT (B) Serum level of BUN. CON, standard
diet group; HC, high-cholesterol diet group; SHSST-L, HC plus 30%
ethanol extract of SHSST treatment group; SHSST-H, HC plus 80%
ethanol extract of SHSST treatment group. Values have been
expressed as the mean ± SEM values of 10 mice per group. ###p <
0.001 vs. CON group. *p < 0.05 vs. HC group, . **p < 0.01 vs. HC group,
***p < 0.001 vs. HC group.
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the average body weight of each group was almost the
same at the starting point, the body weights in the
SHSST-treated group were slightly lower than those in
the HC group in the final week.Effects of SHSST on TC and LDL
Figure 2 shows the concentrations of serum TC and
LDL in each group. The concentrations of TC and LDL
were higher in the HC group than in the other groups.
Administration of SHST significantly suppressed eleva-
tion of the serum TC and LDL levels. In the SHSST-H
group, although there was no statistical significance be-
tween the results for SHSST-L and SHSST-H, the TC
and LDL levels were lower than those in the SHST-L
group.Effects of SHSST on ALT and BUN
The concentrations of ALT and BUN were higher in the
HC group than in any of the other groups (Figure 3). InFigure 4 Effects of SHSST on representative H&E staining of liver tissu
The pictures in the right panel are at the original magnification of 400 × .addition, the level of ALT in the SHSST-H group was
lower than that in the SHSST-L group. In contrast, the
level of BUN in the SHSST-L group was lower than that
in the SHSST-H group. In particular, the level of BUN in
the SHST-treated groups was slightly lower than that in
the CON groups, although no statistically significant dif-
ference was observed between the SHSST-L group and
SHSST-H group. In addition, all toxicity markers in the
SHSST-treated group were within the normal range.Histological examinations
Figure 3 shows the H&E staining results for liver tissues
from each group. In the HC group, lipid droplets ap-
peared as small vacuoles within the liver cells near veins.
Enlargement of lipid droplets in the liver tissue of mice
in the HC group was more pronounced than that in the
SHST-treated groups. Thus, the results for each repre-
sentative tissue clearly showed that lipid accumulation
in the liver was more considerable in the HC group than
in the SHSST-L and SHSST-H groups.e. Pictures in the left panel are at the original magnification of 100×.
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Figure 4 shows the results of western blot analysis. Pro-
tein expression of SREBP2, which is a key transcription
factor involved in cholesterol homeostasis, was downreg-
ulated in the SHSST-treated group relative to that in the
HC group. To determine whether the reduced amount
of lipid droplets in SHSST-treated mice was associated
with expression of hepatic genes involved in lipid and
cholesterol metabolism, we examined the expression of
SREBP2, LXR, LDLR, and HMG-CoA. In liver tissue, the
mRNA expression of SREBP, LXR, LDLR, and HMG-
CoA was clearly lower in the STSST-treated groups than
in the HC group (Figure 5). In addition, the expression
of SREBP2, LXR, and LDLR in the SHSST-H group was
lower than that in the SHSST-L group.Figure 5 Effects of SHSST on liver tissue. (A) mRNA expression of SREBP
SREBP-2. Data were normalized to GAPDH mRNA expression levels and the
value of 1.0. CON, standard diet group; HC, high-cholesterol diet group; SH
H, HC plus 80% ethanol extract of SHSST treatment group. Each bar repres
from each group. ###p < 0.001 vs. control group, *p < 0.05 vs. HC group, **pEffects of SHSST on aorta tissue
The mRNA expression of several molecules in aorta tis-
sue is shown in Figure 6. In the HC group, the mRNA
expression of all the molecules was higher than that in
any other group, and SHSST administration signifi-
cantly suppressed this elevation in mRNA expression.
In addition, the mRNA expression of these molecules in
the SHSST-H group tended to be lower than that in the
SHSST-L group.
Discussion
NAFLD represents a histological spectrum of liver dis-
ease related to diabetes, insulin resistance, and obesity;
this spectrum largely extends from isolated hepatic stea-
tosis to steatohepatitis and cirrhosis. Hepatic steatosis is-2, (B) LXR, (C) LDLR, and (D) HMG-CoA. (E) was Western bolt of
n compared to the values for the CON group, which were assigned a
SST-L, HC plus 30% ethanol extract of SHSST treatment group; SHSST-
ents the mean ± SEM value of 2 independent experiments for 10 mice
< 0.01 vs. HC group, ***p < 0.001 vs. HC group.
Figure 6 Effects of SHSST on aorta tissue. mRNA expression of (A) TNF-a, (B) IL-6, (C) TGF-b, (D) Fibronectin, (E) ICAM, (F) VCAM. Data were
normalized to the GAPDH mRNA levels and then compared to the values for the CON group, which were assigned a value of 1.0. CON, standard
diet group; HC, high-cholesterol diet group; SHSST-L, HC plus 30% ehtanol extract of SHSST treatment group; SHSST-H, HC plus 80% ethanol ex-
tract of SHSST treatment group. Each bar represents the mean ± SEM values of 3 independent experiments for 10 mice from each group. ###p <
0.001 vs. control group, **p < 0.01 vs. HC group, ***p < 0.001 vs. HC group.
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cause of advanced liver disease and is also considered to
be an important cofactor in the pathogenesis of various
other liver diseases [21,22]. The development of hepatic
steatosis is known to be closely associated with genetic
and environmental factors [7,23,24].
The liver plays a central role in cholesterol and lipid me-
tabolism [25]. It is widely assumed that cholesterol metab-
olism is governed by several hepatic genes, including
SREBP-2, LXR, LDLR, and HMG-CoA [26,27]. In particu-
lar, members of the SREBP family such as SREBP1a,
SREBP1c, and SREBP2 are key transcription factors that
are known to control the production of lipids for export
into the bile as micelles and into the serum as lipoproteins[28]. Therefore, the protective effects of SHSST against
liver steatosis may be studied by measuring suppressing of
the expression of those several key hepatic transcription,
especially SREBP-2.
Chronic intake of a high-fat diet has been reported to
cause low-grade inflammation. In addition, excessive
intake of cholesterol may cause vascular inflammation,
and pro-inflammatory cytokines such as TNF-α and IL-6
may stimulate the expression of adhesion molecules and
chemokines such as VCAM-1, ICAM-1, and fibronectin
in aorta tissue [29-31]. VCAM-1 and ICAM-1 are thought
to play an important role in the process of atherosclerosis
by recruiting inflammatory cells, and they are both are up-
regulated by pro-atherogenic factors [31].
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fect of SHSST against hepatic steatosis in mice with
HCD-induced hepatic steatosis. We also used 2 different
types of SHSST extracted using 30% and 80% ethanol to
determine effects of extraction conditions on the efficacy
of SHSST. The reason we decide to study effect of SHSST
on hepatic steatosis specifically is simple and clear: as we
had mentioned before, one of major factor causing
NAFLD is over-substitution of high fat or high cholesterol.
Though, NAFLD is a very comprehensive subject, hepatic
steatosis is one of simple and basic features of NAFLD. To
researchers, it means that demonstrating effect of SHSST
on hepatic steatosis is more efficient way to demonstrate
positive effect of SHSST related with lipid metabolism in
liver specifically. That is why we decided to study SHSST
in liver steatosis induced by HCD. SHSST has various ac-
tive compounds, such as baicalein, baicalin, wogonin, and
berberine. Baicalein has been reported that it can amelior-
ate obesity, dyslipidemia, fatty liver, and diabetes and insu-
lin resistance [32]. Bak et al., reported Wogonin have
beneficial effects on glucose and lipid metabolism related
to enhanced PPARα and adiponectin expression via
AMPK activation [33]. Berberine has effects on NAFLD,
diabetes, and hyperlipidemia [34]. We can suggest that
these components from 3 herbs may be candidates against
hepatic steatosis. The main compound for inhibiting hep-
atic steatosis has to investigate more.
In our study, SHSST clearly suppressed serum TC and
LDL levels relative to those in the HC group. The pro-
tein levels of SREBP, a key transcription factor in choles-
terol metabolism, were also lower in the SHSST-treated
group than in the HC group. In addition, SHSST signifi-
cantly inhibited the hepatic mRNA expression of several
molecules such as SREBP-2, LXR, LDLR, and HMG-CoA
that govern cholesterol metabolism, and it also suppressed
the mRNA expression of TNF-α, IL-6, VCAM-1, ICAM-1,
and fibronectin in aorta tissue, relative to that in the HC
group. These findings suggest that SHSST protected the
liver from hepatic steatosis and aorta tissue from the initi-
ation of atherosclerosis.
In our study, the SREBP-2 expression in protein level
and mRNA expression of several molecules in the liver
and aorta was inhibited to a greater extent in the SHSST-
H group than in the SHSST-L group, which suggests that
the effective component of SHSST may be more efficiently
extracted by using a high percentage of ethanol. It is inter-
esting results. However, this is more than nothing but
local observations and precise studies are needed to inves-
tigate the different pharmacological components between
SHSST-L and SHSST-H. We expect that this issue might
be solved in the near future.
The serum levels of ALT and BUN, which are specific
toxicological markers, are enhanced in the case of liver
injuries and kidney injuries, respectively [35,36]. In thepresent study, SHSST significantly decreased the in-
crease in ALT and BUN levels, relative to those for the
HC group. Thus, SHSST protected the liver and kidney
from possible damage that could resulted from excessive
intake of dietary cholesterol.
Conclusions
Our current investigation clearly demonstrates the pro-
tective effects of SHSST against hepatic steatosis by inhi-
biting the mRNA expression of key hepatic molecules
such as SREBP-2, LXR, LDLR, and HMG-CoA. Our re-
sults also suggest that SHSST may suppress the initi-
ation of atherosclerosis. These findings shed light on a
possible preventative measure against liver steatosis.
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